BiotechTube

KAE609 + IV Artesunate + Coartem

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Severe Malaria

Conditions

Severe Malaria

Trial Timeline

Mar 7, 2022 → Aug 20, 2025

NCT ID
NCT04675931

About KAE609 + IV Artesunate + Coartem

KAE609 + IV Artesunate + Coartem is a phase 2 stage product being developed by Novartis for Severe Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT04675931. Target conditions include Severe Malaria.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04675931Phase 2Completed

Competing Products

20 competing products in Severe Malaria

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
80
Drotrecogin alfa (activated)Eli LillyPhase 2
52
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
77
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
CS-3150Daiichi SankyoPhase 3
77
tacrolimusAstellas PharmaApproved
85
enzalutamideAstellas PharmaPhase 1
33
Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
77
AlefaceptAstellas PharmaApproved
85
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
52
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
77
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
65
CefiderocolShionogiApproved
85
eritoran tetrasodium + PlaceboEisaiPhase 3
77
Donepezil HClEisaiApproved
85
Donepezil Hydrochloride (Aricept)EisaiApproved
85
KHK4827 + PlaceboKyowa KirinPhase 3
77

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85